Lansen Pharmaceutical Holdings Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Lansen Pharmaceutical Holdings hat ein Gesamteigenkapital von $123.6M und eine Gesamtverschuldung von $17.6M, wodurch sich der Verschuldungsgrad auf 14.2% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $175.0M bzw. $51.3M. Lansen Pharmaceutical Holdings Das EBIT des Unternehmens beträgt $12.4M, so dass der Zinsdeckungsgrad -35.1 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $46.4M.

Wichtige Informationen

14.2%

Verhältnis von Schulden zu Eigenkapital

US$17.58m

Verschuldung

Zinsdeckungsgrad	-35.1x
Bargeld	US$46.39m
Eigenkapital	US$123.64m
Gesamtverbindlichkeiten	US$51.34m
Gesamtvermögen	US$174.98m

Jüngste Berichte zur Finanzlage

Recent updates

Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?

Sep 18

Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?

Mar 27

Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet

Sep 27

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

Dec 06

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

Sep 04

We're Not So Sure You Should Rely on Lansen Pharmaceutical Holdings's (HKG:503) Statutory Earnings

Dec 28

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 503Die kurzfristigen Aktiva des Unternehmens ($125.7M) übersteigen seine kurzfristigen Passiva ($49.4M).

Langfristige Verbindlichkeiten: 503Die kurzfristigen Vermögenswerte des Unternehmens ($125.7M) übersteigen seine langfristigen Verbindlichkeiten ($2.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 503 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 503 Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 88.6% auf 14.2% zurückgegangen.

Schuldendeckung: 503Die Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (14.3%) gedeckt.

Zinsdeckung: 503 mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

Lansen Pharmaceutical Holdings Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Lansen Pharmaceutical Updates Withdrawal of Listing of Shares on Stock Exchange

Lansen Pharmaceutical Updates Withdrawal of Listing of Shares on Stock Exchange

Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?

Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?

Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

Recent updates

Lansen Pharmaceutical Updates Withdrawal of Listing of Shares on Stock Exchange

Lansen Pharmaceutical Updates Withdrawal of Listing of Shares on Stock Exchange

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 27%

Investor sentiment improves as stock rises 20%

Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$0.013 (vs US$0.017 in 1H 2022)

New major risk - Revenue and earnings growth

Lansen Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 24, 2023

Investor sentiment improves as stock rises 18%

Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?

Full year 2022 earnings released

Lansen Pharmaceutical Holdings Limited Provides Earnings Guidance for the Twelve Months Ended 31 December 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet

Lansen Pharmaceutical Holdings Limited Appoints Zhu Xun as Independent Non-Executive Director and Member of the Remuneration Committee

First half 2022 earnings released: EPS: US$0.017 (vs US$0.004 in 1H 2021)

Lansen Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Lansen Pharmaceutical Holdings Limited Approves to Elect Chan Ching Har, Eliza as an Independent Non-Executive Director

Investor sentiment improved over the past week

Lansen Pharmaceutical Holdings Limited has completed a Follow-on Equity Offering in the amount of SGD 59.424 million.

Full year 2021 earnings released: EPS: US$0.002 (vs US$0.22 in FY 2020)

Lansen Pharmaceutical Holdings Limited, Annual General Meeting, Jun 23, 2022

Lansen Pharmaceutical Holdings Limited Announces Resignation of Stephen Burnau Hunt as Non-Executive Director and Member of the Remuneration Committee

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Lansen Pharmaceutical Holdings Limited to Report Fiscal Year 2021 Results on Feb 28, 2022

Lansen Pharmaceutical Holdings Limited Announces Executive Changes

Lansen Pharmaceutical Holdings Limited Provides Earnings Guidance for the Year Ended December 31, 2021

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

First half 2021 earnings released: EPS US$0.004 (vs US$0.24 in 1H 2020)

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

Lansen Pharmaceutical Holdings Limited Declares a Special Dividend, Payable on 28 September 2021

Investor sentiment improved over the past week

Chairman recently bought HK$313k worth of stock

Full year 2020 earnings released: EPS US$0.22 (vs US$0.045 in FY 2019)

Lansen Pharmaceutical Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day high: HK$1.92

We're Not So Sure You Should Rely on Lansen Pharmaceutical Holdings's (HKG:503) Statutory Earnings

Chairman recently bought HK$1.4m worth of stock

New 90-day high: HK$0.87

New 90-day high - HK$0.81

Lansen Pharmaceutical Holdings Limited to Report First Half, 2020 Results on Aug 27, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen